Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ∼7% of human malignancies and ∼60% of melanomas. Early clinical experience with a novel clas...